regeneron glp-1 gip treatment muscle loss side effects Optimizing therapies for obesity and diabetes management Targeting Obesity: GLP-1R, GIPR, GDF8

This review provided an in-depth overview of the potential utility and remaining challenges associated with these drug delivery systems, focusing on three main GLP-1RAs, including exenatide, liraglutide, and semaglutide

Tobaiqy, M

Brain insulin resistance in alzheimers disease and related disorders: mechanisms and therapeutic approaches

These lawsuits claim that the drug manufacturers, including Novo Nordisk and Eli Lilly, failed to adequately warn users about the risks of medications such as Ozempic, Wegovy, and Mounjaro

The future directions and challenges of new small-molecule GLP-1R agonists, such as danuglipron, are multifaceted